Galmed Pharma Publishes Aramchol Phase 3 Results
Ticker: GLMD · Form: 6-K · Filed: Sep 25, 2024 · CIK: 1595353
| Field | Detail |
|---|---|
| Company | Galmed Pharmaceuticals LTD. (GLMD) |
| Form Type | 6-K |
| Filed Date | Sep 25, 2024 |
| Risk Level | medium |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: clinical-trials, publication, pharma
TL;DR
Galmed Pharma dropped Phase 3 Aramchol results in Hepatology.
AI Summary
Galmed Pharmaceuticals Ltd. announced on September 25, 2024, the publication of results from the Phase 3 open-label part of its Aramchol study in the journal Hepatology. The press release, filed as an exhibit to this 6-K, details these findings.
Why It Matters
The publication of Phase 3 results in a peer-reviewed journal like Hepatology lends credibility to the study's findings and could influence future development and investment decisions for Aramchol.
Risk Assessment
Risk Level: medium — The filing reports on study results, which can be positive or negative and impact the company's future prospects.
Key Players & Entities
- Galmed Pharmaceuticals Ltd. (company) — Registrant
- Aramchol (drug) — Drug in Phase 3 study
- Hepatology (publication) — Journal where results were published
- September 25, 2024 (date) — Date of press release
FAQ
What specific results from the Aramchol Phase 3 open-label study were published?
The filing states that results from the Aramchol Phase 3 open-label part were published in Hepatology, but the specific details of these results are not included in the 6-K itself, only that a press release was issued.
When was the press release announcing these results issued?
The press release was issued on September 25, 2024.
What is the significance of publishing in Hepatology?
Hepatology is a peer-reviewed medical journal, and publication there indicates that the study results have undergone scientific scrutiny and are considered significant by the journal's editors and reviewers.
Is this filing an annual report?
No, this is a Form 6-K, which is a Report of Foreign Private Issuer, and Galmed Pharmaceuticals Ltd. indicates it files annual reports under Form 20-F.
What is the primary business of Galmed Pharmaceuticals Ltd.?
Galmed Pharmaceuticals Ltd. is in the business of pharmaceutical preparations, as indicated by its SIC code 2834.
Filing Stats: 193 words · 1 min read · ~1 pages · Grade level 10 · Accepted 2024-09-25 08:05:15
Filing Documents
- form6-k.htm (6-K) — 16KB
- ex99-1.htm (EX-99.1) — 18KB
- ex99-1_001.jpg (GRAPHIC) — 62KB
- 0001493152-24-038052.txt ( ) — 121KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Galmed Pharmaceuticals Ltd. Date: September 25, 2024 By: /s/ Allen Baharaff Allen Baharaff President and Chief Executive Officer